Vendor Intelligence Report: Peptronix Bio PTB

Published 13 Jun 2026. 24-page investigative report on who is behind Peptronix Bio PTB: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Peptronix Bio PTB is an active forum-based China peptide vendor with real buyer activity and a narrow but useful Finnrick record. Across 14 Finnrick lab tests the overall result is 12 pass / 2 fail, an 86% pass rate. That supports a cautious GLP-1 read: Retatrutide is the slightly stronger PTB choice, Tirzepatide is close behind, and both lose some shine under stricter grading.

The stronger hook is identity, not chemistry. PTB claims Shenzhen Peptronix Biotechnology Co., LTD, but public registry work did not verify that entity. The domain buyers are pointed toward, peptronix.com, is not a peptide storefront at all; live captures, RDAP/DNS records, and a Wayback trail show an unrelated U.S. consumer-electronics retailer with pre-PTB brand history.

Operationally, PTB offers the bargain profile many buyers look for: direct-message sales, crypto or wire payments, and advertised U.S. warehouse fulfillment. Those same features create the report's highest buyer risks. The warehouse operator and address are undisclosed, ordinary payment recourse is absent, and the communications trail includes WhatsApp impersonation and repeated Discord churn.

The cleanest public conclusion is narrow: PTB is not validated across its 25-plus SKU catalog, but it is a plausible risk-tolerant choice for tested Retatrutide or Tirzepatide buyers who budget for verification. The unresolved questions are COA-to-vial linkage, legal counterparty, and whether domestic stock lowers delivery risk or simply moves the regulatory exposure closer to the buyer.

Inside the full report:

  • Appendix A — Finnrick Laboratory Data with per-product pass/fail rates and methodology-divergence charts for both tested GLP-1s
  • Domain-collision evidence: peptronix.com screenshots, RDAP/DNS notes, and 2015–2025 Wayback history
  • Chinese registry workup for claimed Shenzhen Peptronix Biotechnology Co., LTD and documented search dead ends
  • Contact-channel timeline covering the WhatsApp impersonation warning and Discord invite replacements
  • U.S. warehouse and CBP-related regulatory exposure analysis for Retatrutide/Tirzepatide fulfillment
  • Batch-traceability and vendor-COA provenance review, including Janoshik access limits

Risk assessment

  • Corporate-identity verification risk — high: Claimed Shenzhen Peptronix Biotechnology Co., LTD has no disclosed registration number/address and was not verified in accessible Chinese/public registries.
  • Official-domain and brand-confusion risk — high: PTB promotes peptronix.com, but the live domain is an unrelated DCJ Management, LLC electronics retailer; no verified PTB storefront or official-channels list was found.
  • Payment-recourse risk — high: Orders are crypto/wire only, leaving no card, PayPal, or comparable chargeback path for delivery, substitution, or quality disputes.
  • Regulatory-seizure and undisclosed U.S.-warehouse risk — high: PTB sells Retatrutide/Tirzepatide through China and an undisclosed U.S. warehouse; CBP's March 2026 action targeted the same product categories and China-origin shipment pattern.
  • Product-consistency risk — medium: Retatrutide: 8 tests, 7 pass / 1 fail, 82.4%; Tirzepatide: 6 tests, 5 pass / 1 fail, 79.73% — reasonable but not top-tier, with failures on both tested products.
  • Batch-traceability and COA-provenance risk — medium: Field review found most public samples lacked batch identifiers; without batch-linked vial labels, vendor-posted Janoshik COAs cannot be tied to a buyer's vials.
  • Messaging-channel impersonation risk — medium: A July 2025 impersonation incident disabled the original WhatsApp, and 5+ Discord invite replacements plus no secure storefront increase wrong-counterparty risk.